Holen Sie sich die Stockscreener-App
1.07
14.07%
0.132
Handel nachbörslich:
1.08
0.01
+0.93%
Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB - Sahm
Will NeuroSense Therapeutics Ltd. stock remain a Wall Street favoriteJuly 2025 Trade Ideas & Daily Stock Trend Reports - ulpravda.ru
Is NeuroSense Therapeutics Ltd. stock resilient to inflationGlobal Markets & Weekly High Momentum Picks - ulpravda.ru
Will NeuroSense Therapeutics Ltd. Equity Warrant stock recover faster than peersJuly 2025 WrapUp & Weekly Market Pulse Updates - ulpravda.ru
How NeuroSense Therapeutics Ltd. Equity Warrant stock responds to policy changesWeekly Risk Summary & Weekly High Potential Alerts - ulpravda.ru
Can NeuroSense Therapeutics Ltd. stock resist sector downturnsWeekly Investment Recap & High Return Stock Watch Alerts - ulpravda.ru
Trading Recap: Will NeuroSense Therapeutics Ltd. (H1Z) stock justify high valuation2025 Price Momentum & Fast Gain Stock Tips - ulpravda.ru
Can NeuroSense Therapeutics Ltd. stock continue upward trendBreakout Watch & Free AI Powered Buy and Sell Recommendations - ulpravda.ru
Is NeuroSense Therapeutics Ltd. Equity Warrant stock a good choice for value investors2025 Support & Resistance & Precise Swing Trade Alerts - ulpravda.ru
NeuroSense Therapeutics Ltd. Appoints Prof. Steven E. Arnold to Scientific Advisory Board - MarketScreener
What risks investors should watch in NeuroSense Therapeutics Ltd. stockJuly 2025 Levels & Low Risk Investment Opportunities - ulpravda.ru
Hedge Fund Bets: How NeuroSense Therapeutics Ltd. Equity Warrant stock performs after earningsJuly 2025 Intraday Action & Weekly Setup with ROI Potential - ulpravda.ru
How NeuroSense Therapeutics Ltd. stock benefits from tech adoptionStock Buyback Announcements & Budget Friendly Growth - ulpravda.ru
NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash - TipRanks
How NeuroSense Therapeutics Ltd. stock compares to growth peers2026 world cup usa national team semifinals defensive leaders set piece tactics match prediction analysis - ulpravda.ru
NeuroSense Therapeutics (NASDAQ:NRSN) Upgraded by Wall Street Zen to Hold Rating - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Down 15.5% in December - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets - RTTNews
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study - Sahm
NeuroSense Unveils Favourable Safety Analysis Data Of PrimeC In NST-AD-001 Study For Alzheimer's - Nasdaq
NeuroSense Therapeutics (NASDAQ:NRSN) Receives Buy Rating from D. Boral Capital - Defense World
D. Boral Capital Maintains NeuroSense Therapeutics (NRSN) Buy Recommendation - Nasdaq
NeuroSense Reports Favorable Safety Profile for PrimeC in Phase 2 Alzheimer’s Trial - TipRanks
Neurosense stock rises as Alzheimer’s drug shows favorable safety profile By Investing.com - Investing.com South Africa
Neurosense stock rises as Alzheimer’s drug shows favorable safety profile - Investing.com
Experimental Alzheimer's combo shows no serious side effects in trial - Stock Titan
Why NeuroSense Therapeutics Ltd. Equity Warrant stock appeals to analysts2025 Bull vs Bear & Low Risk High Reward Trade Ideas - Улправда
Forecast Cut: Why NeuroSense Therapeutics Ltd. Equity Warrant stock appeals to analystsBuy Signal & Daily Momentum Trading Reports - Улправда
Rally Mode: Is Capella Minerals Limited (N7D) stock worth buying before Fed actionEarnings Overview Summary & Safe Capital Investment Plans - moha.gov.vn
Will NeuroSense Therapeutics Ltd. stock pay special dividends2025 Volume Leaders & Verified Swing Trading Watchlists - Улправда
ETF Watch: Can NeuroSense Therapeutics Ltd. (H1Z) stock sustain institutional flowsJuly 2025 Recap & Fast Gain Swing Trade Alerts - DonanımHaber
How NeuroSense Therapeutics Ltd. (H1Z) stock compares with tech leaders2025 Stock Rankings & Low Volatility Stock Suggestions - Улправда
It had formed inverted head and shoulders earlier soon it gave a break out of the pattern.2025 Historical Comparison & High Conviction Buy Zone Alerts - Bollywood Helpline
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requi - GuruFocus
Whale Trades: What dividend safety rating applies to NeuroSense Therapeutics Ltd H1Z stockJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - moha.gov.vn
NeuroSense Therapeutics Schedules Shareholder Meeting to Approve Equity Compensation - MSN
Wall Street Zen Downgrades NeuroSense Therapeutics (NASDAQ:NRSN) to Sell - Defense World
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
A better buy-in window may exist right now for Lexicon Pharmaceuticals Inc (LXRX) - setenews.com
NRSN: PARAGON phase III ALS trial starts mid-2026, with strong data, FDA clearance, and global scope - TradingView — Track All Markets
NRSN: Global phase III ALS trial set for mid-2026, with strong efficacy and active partnership talks - TradingView — Track All Markets
NeuroSense Completes Data Collection for Alzheimer’s Trial - TipRanks
NeuroSense (NRSN) locks RoAD Phase 2 Alzheimer’s trial database, eyes Q1 2026 data - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Will NeuroSense Therapeutics Ltd. (H1Z) stock outperform value peersEarnings Summary Report & Daily Oversold Stock Bounce Ideas - Newser
How strong is NeuroSense Therapeutics Ltd. Equity Warrant stock balance sheetMarket Performance Report & Verified Short-Term Trading Plans - Newser
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 - Nasdaq
NeuroSense Therapeutics LtdResuming regulatory advancement in Canada for PrimeC in amyotrophic lateral sclerosis - marketscreener.com
NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug - TipRanks
Neurosense Therapeutics LtdResuming Regulatory Advancement In Canada For Primec In Amyotrophic Lateral Sclerosis - TradingView
Is NeuroSense Therapeutics Ltd. stock overvalued by current metricsMarket Growth Review & Capital Protection Trading Alerts - Newser
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):